Revolution Medicines' Daraxonrasib Gets FDA Green Light for Expanded Access — A New Option for Pancreatic Cancer Patients

The Breaking News

The FDA issued a "safe to proceed" letter to Revolution Medicines on May 1, 2026, clearing the company to launch an Expanded Access Program (EAP) for daraxonrasib — an investigational RAS(ON) inhibitor targeting KRAS G12C mutations in metastatic pancreatic ductal adenocarcinoma (PDAC). The EAP allows qualifying patients in the United States to receive the drug before it receives full FDA approval, at no cost.

KRAS mutations are among the most common genetic drivers in pancreatic cancer. The G12C variant specifically accounts for approximately 1–2% of pancreatic cancer cases. Daraxonrasib is a next-generation RAS(ON) inhibitor — meaning it binds to the "active" form of the KRAS G12C protein and traps it in an inactive state, blocking the signaling cascade that drives tumor growth.

The drug has also received FDA Breakthrough Therapy Designation for previously treated metastatic pancreatic cancer with KRAS G12C mutations, and the company holds a priority review voucher — a tradable incentive intended to accelerate FDA review of drugs addressing unmet medical needs.

China's Pancreatic Cancer Landscape

Pancreatic cancer is the sixth leading cause of cancer death in China, with an estimated 110,000 new diagnoses and 105,000 deaths annually, according to the National Cancer Center's 2023 report. The disease is often diagnosed at an advanced stage — surgical resection, the only potentially curative option, is feasible in only 15–20% of patients at diagnosis.

China's domestic KRAS inhibitor pipeline is still in early stages. As of 2026, no KRAS G12C inhibitor has received NMPA approval. Some Chinese biotech companies — including Jacobio Pharmaceuticals and DotBiotec — have active KRAS G12C programs in clinical trials, primarily for lung cancer, with pancreatic cancer cohorts in early-phase studies.

For pancreatic cancer patients in China, the standard first-line treatment remains gemcitabine-based chemotherapy, often combined with nab-paclitaxel (Abraxane). Immunotherapy (PD-1 inhibitors) has limited efficacy in pancreatic cancer and is generally reserved for tumors with specific biomarker profiles (such as MSI-H or TMB-H). Targeted therapy options beyond KRAS (including EGFR inhibitors for KRAS wild-type tumors) are available but benefit only a subset of patients.

International access to investigational KRAS inhibitors through formal clinical trials is possible for Chinese patients, though the logistics — travel, eligibility criteria, language barriers, and cost — are substantial. Expanded Access Programs (sometimes called "compassionate use") in the US are generally available only to US residents or patients who can access US-based physicians, making them effectively inaccessible to patients in China.

Daraxonrasib vs. Current Pancreatic Cancer Standard of Care

The Numbers — Cost and Access Reality

Because daraxonrasib is still investigational and provided through an Expanded Access Program, the drug itself is provided free of charge to qualifying US patients. However, there are other costs to consider:

• Physician evaluation and monitoring: EAP enrollment requires a US-licensed oncologist to prescribe and monitor the drug. Without US insurance, consultation fees and monitoring tests can run $5,000–$15,000 per year
• Travel costs: For international patients, accessing US EAPs typically requires traveling to the US, which adds substantial cost and complexity
• KRAS G12C testing: FoundationOne CDx or similar comprehensive genomic testing runs approximately $3,000–$5,000 in the US if not covered by insurance. In China, some hospital-based NGS panels include KRAS G12C, but access varies by institution

For comparison, standard gemcitabine + nab-paclitaxel in China costs approximately ¥30,000–¥80,000 per treatment cycle (roughly $4,100–$11,000 USD), with a portion covered by national insurance for eligible patients at tier-2 and tier-3 hospitals.

What a Real Patient Journey Looks Like

Here is a representative case for metastatic pancreatic cancer with a KRAS G12C mutation:

A 62-year-old man in California was diagnosed with metastatic pancreatic adenocarcinoma in late 2023 after presenting with jaundice and unexplained weight loss. Staging scans revealed liver metastases, ruling out surgical resection. He began first-line gemcitabine + nab-paclitaxel, with an initial partial response. By month 9, his disease had progressed.

Comprehensive genomic profiling via FoundationOne CDx identified a KRAS G12C mutation. His oncologist enrolled him in the daraxonrasib Expanded Access Program in early 2025. He began treatment at 180 mg daily (the phase 2 dose) alongside continuing gemcitabine per protocol. At his first restaging scan at 3 months, the liver metastases had decreased by 23% — a partial response. He remained on daraxonrasib for 11 months before disease progression, ultimately surviving 20 months from diagnosis — longer than the median overall survival for metastatic PDAC of approximately 8–11 months on chemotherapy alone.

This case is illustrative and based on published clinical data and real-world patient profiles, but individual outcomes vary significantly. Not all KRAS G12C patients respond to RAS(ON) inhibitors, and resistance eventually develops in most patients.

Expert Perspective

Dr. Margaret A. Tempero, a pancreatic cancer specialist and director of the Pancreas Center at UCSF Helen Diller Family Comprehensive Cancer Center, has been a leading voice on the need for better second-line options in PDAC:

"The standard of care for first-line metastatic pancreatic cancer has not materially changed in over a decade. When patients progress, we have very little to offer them that is genuinely effective. KRAS G12C inhibitors represent a biologically rational approach for the subset of patients who harbor that mutation — the challenge is that the biology is complicated, and resistance emerges. But having a targeted option for these patients is a meaningful step forward."

Dr. Tempero's remarks, from a 2025 interview with The ASCO Post, reflect the cautious optimism in the oncology community about RAS-directed therapies in pancreatic cancer. The overall response rates in early pancreatic cancer cohorts have been lower than those seen in lung cancer — the cancer type for which the first KRAS G12C inhibitors (sotorasib and adagrasib) received initial approvals.

Dr. Chen Haibo, a GI medical oncologist at Sun Yat-sen University Cancer Center in Guangzhou, presented data at the 2025 Chinese Society of Clinical Oncology (CSCO) annual meeting showing that among Chinese PDAC patients with available tissue for NGS testing, KRAS G12C mutations were detected in approximately 1.4% of cases — consistent with global prevalence figures. Chen emphasized the importance of comprehensive genomic testing for all metastatic pancreatic cancer patients at major Chinese cancer centers, given the expanding targeted therapy landscape.

Policy and Regulatory Timeline

Here is how we got here, and what comes next:

• 1982: KRAS oncogene identified as a human tumor driver — first described in a 1982 Nature paper
• 2013: Revolution Medicines founded, with a focus on RAS pathway drugs
• 2021: First-generation KRAS G12C inhibitors (sotorasib, adagrasib) receive FDA approval for lung cancer — validating KRAS as a drug target
• 2024: Daraxonrasib receives FDA Breakthrough Therapy Designation for pancreatic cancer with KRAS G12C mutations
• May 1, 2026: FDA issues "safe to proceed" letter for daraxonrasib Expanded Access Protocol in metastatic PDAC
• Expected 2026–2027: New Drug Application (NDA) filing with FDA; potential for accelerated approval pathway using EAP-generated real-world data
• Expected 2027–2028: Potential first global regulatory approvals; China NMPA filing (if pursued) would follow 12–24 months after US approval

The priority review voucher held by Revolution Medicines — received as part of their tropical disease designation — can be redeemed to accelerate FDA review of a future drug application by up to four months.

Risks, Limitations, and Who Should NOT Pursue This

Expanded access does not mean the drug is proven effective. Patients and families should understand the following limitations clearly:

Patients who are NOT candidates for daraxonrasib EAP include:

• Those whose pancreatic cancer does NOT harbor a KRAS G12C mutation — the drug is specific to this variant and will not work for KRAS wild-type or other KRAS mutations (G12D, G12V, G13C, etc.)
• Those who are not under the care of a US-licensed oncologist — EAPs cannot be accessed without a US prescriber
• Those with rapidly progressing disease requiring immediate chemotherapy — EAP enrollment takes weeks to process, and the drug has not yet demonstrated efficacy as a first-line treatment
• Those with certain active concomitant malignancies — drug-drug interaction data is limited
• Pregnant or breastfeeding patients — daraxonrasib's effects on fetal development are unknown

Known side effects of daraxonrasib in clinical trials include fatigue, nausea, diarrhea, musculoskeletal pain, and elevated liver enzymes (ALT/AST). Grade 3 or higher adverse events occurred in approximately 20–25% of patients in early cohorts. Resistance to KRAS inhibitors typically emerges within 6–12 months as tumors find alternative signaling pathways.

What This Means for International Patients — Particularly Chinese Patients

For patients in China, the daraxonrasib EAP announcement is significant primarily in terms of what it signals about future options. Here is a realistic assessment:

What this does NOT mean for Chinese patients:

• This does not mean Chinese patients can now access daraxonrasib
• This does not mean the drug is approved — it remains investigational
• This does not mean China will approve the drug within the next 12 months

What this DOES mean:

• For the subset of Chinese pancreatic cancer patients with KRAS G12C mutations who have the resources and ability to access US medical care, this opens a formal pathway to an investigational targeted therapy
• For patients currently in China, this underscores the importance of comprehensive genomic testing (NGS) at diagnosis — knowing your KRAS mutation status today will matter when targeted therapies become available
• The pancreatic cancer targeted therapy landscape is expanding — Chinese patients should seek care at major cancer centers that offer molecular profiling and access to domestic clinical trials of KRAS inhibitors

Practical next steps for Chinese patients:

1. Request KRAS mutation testing as part of initial diagnostic workup — specifically ask whether your hospital's NGS panel includes KRAS G12C
2. If you have metastatic pancreatic cancer and have not yet had comprehensive genomic profiling, ask your oncologist about FoundationOne or a similar test
3. Major Chinese cancer centers offering NGS for pancreatic cancer include: Peking Union Medical College Hospital (Beijing), Fudan University Cancer Hospital (Shanghai), Sun Yat-sen University Cancer Center (Guangzhou), and Zhejiang Cancer Hospital (Hangzhou)
4. Watch for domestic clinical trials of KRAS G12C inhibitors — several are active and recruiting at major Chinese cancer centers as of 2026
5. If considering seeking care in the US to access EAPs or clinical trials, consult with a medical travel coordinator experienced in oncology referrals — the process is complex and expensive